Benign familial hematuria (BFH) is characterized by auto somal dominant inheritance, thinning of the glomerular basement membrane (GBM) and normal renal function. It is frequent in patients with persistent microscopic hema turia, but cannot be clinically differentiated from the initial stages of Alport syndrome, a severe GBM disorder which progresses to renal failure. We present here linkage of be nign familial hematuria with the COL4A3 and COL4A4 genes at 2q35-37 (Z max = 3.58 at 0 = 0.0). Subsequently, a glycine to glutamic acid substitution was identified in the collagenous region of the COL4A4 gene. We conclude that type IV collagen defects cause both benign hematuria and Alport syndrome. Furthermore, our data suggest that BFH patients can be carriers of autosomal recessive Alport syn drome. (J. Clin.
Introduction
Hematuria is the presenting symptom in a large number of re nal disorders. If the hematuria occurs in childhood, is isolated and is of glomerular origin, die diagnosis is difficult to reach. Benign hematuria, Alport syndrome and IgA-nephropathy all present with persistent hematuria. Particularly, differentiation between Alport syndrome, which is a severe renal disorder, progressing to renal failure in most cases, and benign hema turia is mandatory for correct prediction of prognosis and ge netic counseling. In benign hematuria electron microscopic analysis of renal biopsies shows thinning of the glomerular basement membrane (G B M )1 (1-3), while in Alport syndrome renal biopsies are characterized by irregular thickening and multilamination of the GBM (4) . However, thinning of the G B M may be the only microscopic abnormality in younger Alport patients (5-7), which hampers the differentiation be tween the two disorders in childhood. Renal biopsies of 65 children with isolated hematuria persisting for at least one year revealed histological abnormalities consistent with Alport syn drome in eight cases and consistent with benign hematuria in 33 cases (3) . A positive family history was detected in 23 of the 33 cases.
The major structural component of the GBM is formed by a type IV collagen network. As yet, six different type IV col lagen chains have been identified and the respective genes were cloned. Mutations were detected in three type IV col lagen genes in Alport syndrome, The majority was present in the X-linked type IV collagen a5 (COL4A5) gene, but re cently mutations in the type IV collagen a3 and a4 (COL4A3/ A4) genes have been reported in patients with the autosomal recessive form of this disease (8, 9) , These tatter two collagen genes are localized head to head on the tip of the long arm of chromosome 2 (10). Considering the similarities in GBM ab normalities, autosomal Alport syndrome and BFH could be the severe and mild forms of different molecular genetic de fects in the same genes. Here we report linkage of the COL4A3/A4 locus to BFH in a large Dutch family (11) and the identification of a pathogenic mutation in the COL4A4 gene.
Methods
Patients. The index patient (111:10; see Fig. 1 ) presented with hema turia at the age of 5 years. There were no concomitant abnormalities, i.e., glomerular filtration rate was normal and hypercalciuria was ab sent. There was also no hypertension. The morphology of the eryth rocytes in the urinary sediment indicated a glomerular origin of the cells. Audiography and fundoscopy revealed no abnormalities. Fam ily history was negative for renal failure and deafness. One year later a renal biopsy was performed. Electron microscopy of the biopsy specimen showed regions with malformations of the glomerular base ment membrane, typical for Alport syndrome, and regions which were thin. Further investigation of the family showed microscopic he maturia in both parents and his younger brother ( 111:11), but no other symptoms suggestive for Alport syndrome. Renal function was nor mal in the parents (11:7 and 11:8; normal serum creatinine concentra tion). Microscopic hematuria was present in three sisters of the father (11:7) and in half of their off-spring, as well as in the grandfather (1:1 ; Fig. 1 ). Particularly important is that this 75-yr-oId man had a normal serum creatinine concentration. In the family of the mother (11:8) he maturia was also widely present. Her 76-yr-old father had hematuria and a normal creatinine level, her mother was healthy. It was con-eluded that the family history on both sides strongly supported the di agnosis BFH. The index patient might have inherited the disorder form both parents, which could explain the aberrant morphology of the biopsy specimen. He is presently 16 years old and symptoms are hematuria and recently developed proteinuria (0.5 grams/liter). H e maturia was defined as a condition with 10 or more erythrocytes per mm3 urine, established by the quantitative sediment method of Gadeholt (12) . Individuals with borderline values were repeatedly ana lyzed. All family members could unambiguously be scored as either affected or unaffected. Linkage analysis. Blood samples were collected from family members and genomic D N A was isolated by a salting out procedure (13) . The COL4A3/COL4A4 CA repeat was PC R amplified using 125 ng of primers C A I IF (5'-ATC TCT C A G G G T G C G TGC-3') and CA11R (5'-CTC ATT G AT A C A C A C A A A T G C A-3') and 50-100 ng D N A template in a standard Cetus buffer with 2 m M MgCl2. After 3 min at 94°C, four initial cycles were performed of 1 min at 94°C, 1 min at 58°C and I min at 72°C followed by 30 cycles of 1 min at 94Q C, 1 min at 55°C and 1 min at 72°C. One of the primers was fluorescently labeled and the PCR product was analyzed on an A B f 373A Automated Sequencer using the Genescan software package (Applied Biosystems, Foster City, CA). A COL4A4 H ae lll RFLP was identified by SSCP and subsequent sequence analysis and is caused by a neutral mutation at the J198glycine residue of the COL4A4 gene. PCR was performed on 100 ng genomic D N A using 100 ng of intronic oligonucleotides A41F10 (5'-AGGCACTATAAC-A G G G ACAA G A -3') (9) and 714 (5'-CCTCATTGCATTTGGAAG-GT-3'), 200 jjlM dNTPs, 5% DM SO in Ampli-Taq buffer containing 67 mM Tris-HCl (pH = 8.8), 16.6 mM (NT-ySO,,, 6.7 mM MgCU, 0.17 mg/ml BSA (Boehringer Mannheim, Germany) to a total volume of 25 ju lI. The sequence of oligo 714 is the reverse of oligonucleotide A41F9 (9) . After 5 min of dénaturation at 96°C 1 U Ampli-Taq D N A polymerase (Perkin-Elmer, Norwalk, CT) was added ancl 30 cycles of PCR were started (dénaturation at 94°C for 1 min, annealing at 62°C for I min and extension at 72°C for 1 min and 30 s). if the H ae lll site is present, digestion of the PCR fragment (260 bp) gives two bands of 182 and 78 bp (data not shown).
Two point and multi-point lod scores were calculated using the M LINK and LINICMAP options of the L IN K A G E package com puter program (version 5.03) (14). B F H was defined as an autosomal dominant disorder with complete penetrance. The disease frequency was estimated to be 0.0001. Mutation analysis. R N A was isolated from peripheral blood lymphocytes (PBL) or E B V transformed PB L from affected and nor mal individuals by R N A zo l extraction (15) . COL4A3 and COL4A4 cD N A fragments were generated by RT-PCR analysis as described before (8, 16) . Oligonucleotides were designed to amplify COL4A3 and COL4A4 cD N A by multiple overlapping cD N A fragments. D N A fragments were sequenced on an A B I 373A automated se quencer. Reaction conditions using dyedeoxy''^-terminators were ac cording to a protocol provided by the manufacturer (Applied Biosys tems, Foster City, C A ). The GIy897Glu mutation was identified in the P C R fragment, flanked by outer primers 945 (5'-GCGAAG-G G T G A C A T G GTT G T A T C A -3 ' ) starting at position 1871 and 946 (5'-CCTCTC A G A A G GTC A A C A C T C C C A G -3' ) starting at position 4074 (17) in a first round of 35 cycles; dénaturation for 1 min at 92°C, î min 30 s of annealing at 60°C and extension for 3 min at 72°C. Two microliters out of the first P C R reaction was used as template for a second round of 35 cycles using inner primers FlOO (5'-AAGGCC-TCCCCGGACTCCCA-3') at position 2750 and R101 (S'-CGGGAG-GTCCTATGGCTC-3') at position 3017 (17); dénaturation for 1 min at 92°C, 1 min 30 s of annealing at 55°C and extension for 2 min at 72°C. The GJy897Glu mutation created an A lu l restriction site and was screened at the genomic D N A level by PC R amplification using oligonucleotides F100 (5
'-A A G G C C T C C C C G G A C T C C C A -3') and 1106 (5 '-A C C T G G A G G A C C A G G T A G C -3 ') and digestion with
A lu l restriction enzyme (G IB C O B R L , Gaithersburg, M D ). If the mutation is present the 104-bp PC R fragment is cleaved in two frag ments of 86 and 18 bp. The smallest fragment is not visible.
Results
Linkage analysis. Linkage analysis was performed with two novel polymorphic markers from the COL4A3/COL4A4 lo cus. The most informative marker was a C A repeat, isolated from a Y A C clone with an insert of 540 kb, containing both COL4A3 ancl COL4A4 genes (18) . The other marker was a Linkage analysis was performed in the paternal (11:7) side of the pedigree (Fig. 1) . The mother (11:8) and her two sons, 111:10 and 111:11 (Fig. 1) , were not included in the linkage stud ies, because BFH segregated also in the maternal line. The maternal relatives were not available for linkage analysis. A maximum lod score (Zmax) of 3.01 was obtained in the paternal (11:7; Fig. 1 ) line with the COL4A3/COL4A4 CA repeat at re combination fraction (0) of 0.0 in our family. The Z m ux ob tained with the intragenic COL4A4 RFLP is 1.51 at 0 -0.0.
All affected individuals share the haplotype [78, 2] for both markers (Fig. 1) . This haplotype was linked to BFH with a Zm nx of 3.58 at 0 = 0.0 . Mutation analysis. RT-PCR was performed on total lym phocyte RN A followed by direct sequence analysis of ampli fied COL4A3 and COL4A4 cDNA fragments. A heterozy gous G to A nucleotide substitution was identified at position 2898 of the COL4A4 gene in the patients 111:10 and 111:11 and in their father 11:7, but not in their mother 11:8. The glycine codon G G G at position 897 was changed into G A G , encoding a glutamic acid residue (Fig. 2) . The mutation introduced a novel site for the restriction enzyme A lul and the other family members and controls were screened for the presence of this site. If the A lul site is present, a 104 bp PCR fragment will be cleaved in two smaller fragments of 86 and 18 bp (Fig. 2 ). All affected family members were heterozygous for the mutation (Fig. 3 ) and the mutation was not detected in the unaffected family members and 50 unrelated controls (data not shown).
drome. This is in line with the histological examination of the kidney biopsy and the presence of proteinuria in the index pa tient, who is a suspected compound BFH heterozygote. The definite proof awaits the detection of the second maternal BFH mutation and the progression of his renal disease.
In conclusion, this is the first report on a genetic defect ex plaining benign hematuria. The identification of type IV col lagen defects, similar to those found in Alport syndrome, is im portant for genetic counseling and prognostic prediction. As yet, this prediction can not be based on the mutation only, but needs a compiete investigation of family history, follow-up ex amination and renal biopsy. In a recent report linkage of the rare autosomal dominant form of Alport syndrome to the type IV collagen a3 and a4 locus was demonstrated in a large Northern-Irish family (Jefferson, J.A., A.P. Maxwell, A.E. Hughes, C.M. Hill, C.C. Doherty, and N.C. Nevin. Autosomal dominant Alport syndrome linked to the type IV collagen o¿3 and a4 genes (COL4A3 and COL4A4), manuscript submitted for publication). It is obvious that the type IV collagen a3 and cx4 genes are strong candidates for the autosomal dominant form of Alport syndrome as well. This would complete the spectrum of phenotypes of type IV collagen o¿3 and u.4 defects, ranging from neutral amino acid substitutions (8) and benign hematuria to mild autosomal dominant and severe recessive Alport syndrome. In this way, the type IV collagen mutations fit within the rule of extreme clinical and genetic variability of collagen disorders (21).
Discussion
For several reasons, the Gly897Glu mutation in the type IV collagen o¿4 chain is likely to be the pathogenic mutation in the BFH family. First, the mutation changes a glycine in a con served collagenous triple helical domain in the type IV col lagen a4 chain (17) . Every third amino acid is a glycine, be cause it is the only residue small enough to fit into the center of the triple helical molecule (19) . If glycine residues are substi tuted by bulkier amino acids such as glutamic acid the triple helix structure will be distorted (Fig. 2) . Unlike fibrillar collagens, type IV collagen triple helices contain 21-26 interrup tions, which are assumed to provide flexibility to the molecule. However, the positions of these interruptions are highly con served during evolution and the generation of an additional in terruption may interfere with correct folding of the intricate type IV collagen tri mers, consisting of type IV collagen ct3, c¿4, and c¿5 chains. Substitutions for glycines in the collagenous tri ple helical domain are also a common cause of other collagen disorders, like osteogenesis imperfecta and Ehlers D anlos syn drome (20) . Furthermore, the mutation cosegregates with BFH in our family and, finally, the mutation is absent from a control group of 50 individuals, which provides additional evi dence for the pathogenicity of the defect.
In 1994, homozygous mutations in the type IV collagen tx3 and a4 genes have been identified in patients with autosomal recessive Alport syndrome (8, 9) . Two different mutations were reported in the type IV collagen c¿4 gene: a glycine to serine substitution and a serine to stop mutation (9) . Similar to the Gly897Glu mutation in the BFH family presented here, the glycine is substituted in the triple helical domain of the type IV collagen a4 chain. Our data suggest that BFH patients can be manifesting carriers of autosomal recessive Alport syn-
